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Prenatal diagnosisHemophilia B has been considered as a classical monogenic disorder with complete penetrance. Here, we
observed that its allelic spectrum encompasses mutations that show least phenotypic variation as well as
those showing phenotypic plasticity, thereby establishing hemophilia B as a quasi-quantitative condition
with variable expressivity. Thus, we relocate it from simple monogenic diseases with complete penetrance
into a space that marks the conceptual continuum of Mendelian to complex diseases. By computational
analysis, we show that mutations showing phenotypic variation were characterized by relatively less
conserved mutant sites and more tolerated conservative substitutions. We also demonstrate that
consideration of continuous phenotypes renders quantitative rigor for interrogation and hence higher
predictive value while analyzing for differential properties than classiﬁcations based on clinical end points.
Certain mutations have been consistently reported to cause mild phenotype, calling for a check in
indiscriminate termination of fetuses following prenatal diagnosis.
© 2009 Elsevier Inc. All rights reserved.Introduction
Defects in factor IX levels or activity caused by mutations in factor
IX gene (F9) lead to the X-linked recessive rare bleeding disorder
hemophilia B (MIM# 306900). Based on the plasma levels of factor IX
among affected individuals, the disease is classiﬁed as severe,
moderately severe or mild with respect to normal factor IX activity
assayed in the patients' plasma (b1%, 2–5%, 6–30% respectively).
Clotting activities are routinely measured using one-stage clotting
assay [1]. This activated partial thromboplastin time (APTT) based
assay assesses the interaction between a large number of clotting
factors. The deﬁciency in the factor IX levels or activity is reﬂected by
prolonged APTT relative to the normal plasma and is used to calculate
the clotting activity.
Hemophilia B is considered to be a classical monogenic disorder
with complete penetrance. However, recently, we identiﬁed this
disease with remarkable allelic heterogeneity as a testimony of
“identical mutations with varying phenotypes” phenomenon [2] and
speculated that this might be a replacement-speciﬁc property [3]. By
analyzing the properties of missense mutations that cause more than
one clinical end point we attributed this clinical variation tomutations
at evolutionarily less conserved sites and contemplated hemophilia B
to be a deviation from classical Mendelian disorder with complete
penetrance [4].ll rights reserved.Nevertheless, to comprehensively account for the degree of
phenotypic plasticity that each mutation exhibits, it is desirable to
consider clotting activity as continuous phenotype by abandoning
clinical discriminations. Furthermore, usage of clinical cut-offs often
lead to categorical labeling of an otherwise continuous trait, and
hence is invariably subjective. This makes consideration of conti-
nuous variables more informative than discrete variables. Therefore
here, we considered clotting activity as a continuous trait and have
attempted stratifying the missense mutations based on the mean
deviation about the geometric mean using unsupervised clustering.
This has led to the identiﬁcation of three clusters with two showing
phenotypic plasticity and one with very little variation, if any. We
have then compared the clusters for their sequence and structural
properties.
Results and discussion
Phenotypic plasticity in hemophilia B
Based on the clotting activities reported for each F9 mutation in
the Haemophilia B mutation database [5], we classiﬁed the
mutations with at least two reports into distinct clusters using K-
means clustering. This stratiﬁcation identiﬁed three clusters viz.,
cluster 1 (n=11), cluster 2 (n=33) and cluster 3 (n=157) with
centroids 9.17, 4.00 and 0.45, respectively (Supplementary Table 1).
Thus, mutations belonging to clusters 1 and 2 exhibit quantitative
variation in clotting activity as is obvious from the value of centroids
while mutations in cluster 3 express uniform phenotype. Analysis of
Fig. 1. Evolutionary conservation of mutant site amino acids belonging to the three
clusters. (A) Distribution of mutant site amino acids among the four classes of
traditional descriptors of conservation viz., Generic (G), Partially generic (P), factor IX
Speciﬁc (S) and Non-Conserved (N) [11]. Most of the cluster 3 residues are highly
conserved (60.5% generic) in comparison to the other two clusters (27.3% and 30.3% in
clusters 1 and 2, respectively). (B) Conservation status of the mutant site residues as
deﬁned by scorecons values. Larger part of residues in cluster 3 (74%) have a scorecons
value≥0.7 while major fraction of the residues in the other clusters (72.7% and 66.7% in
clusters 1 and 2, respectively) have values b0.7.
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database identiﬁes an average of 8.57 reports per mutation in the
clusters 1 and 2 compared to only 4.99 reports per mutation in
cluster 3. This clearly indicates a higher prevalence rate of the cluster
1 and cluster 2 mutations and hence their higher contribution to the
disease.
It is evident from the clustering that the allelic spectrum of
hemophilia B encompasses F9 mutations that show least pheno-
typic variation (qualitative—cluster 3) as well as those showing
phenotypic plasticity (quantitative—clusters 1 and 2). This ﬁnding
establishes hemophilia B as a quasi-quantitative condition thus,
identifying a new class of human genetic diseases. Based on this,
we relocate hemophilia B from the section of simple monogenic
diseases with Mendelian transmission into a space which marks
the conceptual continuum of Mendelian to complex diseases. With
mutations that show both qualitative and quantitative behavior
hemophilia B would serve as a good model to understand complex
human diseases. Often studies that consider phenotypic variation
in human monogenic diseases are perceived to be inﬂuenced by
inter-laboratory assay differences. Such a contradiction in our
study is emphatically put to rest as the phenotypic plasticity
observed for certain mutations are several orders greater in
magnitude than that would otherwise result from inter-laboratory
assay variations of clotting activity measurements as explicitly
demonstrated previously [6].
It is intriguing that while certain mutations in a gene lead to a
homogeneous phenotype others exhibit variation. This prompted us
to investigate for differences in the intrinsic properties of mutations.
Hence, we examined the differences among these three clusters for
sequence-based and structural properties.
Evolutionary conservation of the mutant site
Comparison of evolutionary conservation of mutant site residues
assigned by traditional method and scorecons revealed signiﬁcant
differences among the three clusters (P=2.4×10−7, ANOVA
P=6.1×10−7, respectively) with preponderance of generic residues
in cluster 3 in contrast to the cluster 1 and cluster 2 (Figs. 1A and B).
Pairwise comparisons of scorecons revealed signiﬁcant differences
between cluster 1 and cluster 3 (P=1.7×10−4); and between
cluster 2 and cluster 3 only (P=6.7×10−5). The major fraction of
cluster 3 residues was highly conserved in contrast to those of the
other two clusters. Thus the degree of evolutionary conservation of a
mutant site signiﬁcantly inﬂuences the tendency of mutations to
express phenotypic plasticity. Further, it is noteworthy that cluster 2
mutations do not show drastic variation in their occurrence across
generic, partially generic, and factor IX speciﬁc residues (Fig. 1A) as
compared to the other two clusters. This partly explains as to why
cluster 2 shows an intermediate centroid with respect to the clotting
activity. When the mutant site amino acid distribution proﬁle among
the cluster 3 mutant sites and those that show phenotypic plasticity
(clusters 1 and 2) was examined, we found a statistically signiﬁcant
difference (P=0.001). The predominant mutant sites in cluster 3
were Cys and Gly (22% and 17%, respectively). All the Cys residue
mutations in cluster 3, except one, affect the sites that are involved
in the formation of disulﬁde bonds. Gly, owing to the lack of side
chain, is known to occur frequently in turn regions of a protein
where other residues would bring about steric hindrance. These
mutant sites indicate that cluster 3 mutations might affect the
structural integrity of the factor IX protein and hence are less
dispensable to normal function.
Effect of substitution
We identiﬁed that substitutions leading to high phenotypic
variance are more tolerated compared to the ones with no variance.This is evidenced from signiﬁcant differences in PSIC values (ANOVA
P=1.7×10−8) among the three clusters (Fig. 2A). This variation was
caused by differences of cluster 3 with clusters 1 and 2 (P=1.5×10−4
and 1.1×10−6, respectively), withmajority of substitutions in clusters
1 and 2 being relatively more tolerated in sharp contrast to that of
cluster 3. Similar observations were made using SIFT. We observed
signiﬁcant differences in the distribution of deleterious substitutions
among the three clusters (χ2trendP=1.2×10−6; Fig. 2B). However, the
differences in distribution were observed only between cluster 3 with
clusters 1 and 2 (P=2.5×10−5 and 2.2×10−5, respectively). Clusters
1 and 2 had comparable distribution of deleterious and tolerated
substitutions.
We could not distinguish physicochemical constraint violation as
evaluated by MAPP score among the three clusters. Grantham
difference assessment identiﬁed signiﬁcant differences among the
three clusters (P=2.0×10−4) with almost half of cluster 3 substitu-
tions being radical while majority of substitutions in clusters 1 and 2
are conservative (Fig. 2C). This establishes phenotypic variation to be
a property of conservative substitutions.
Structural properties and phenotypic variance
Polyphen classiﬁed 46% of cluster 1 and 39% of cluster 2 as
benign compared to 15% in cluster 3, 27%, 15% and 6%, respectively,
as possibly damaging and 27%, 46% and 79% as probably damaging
among the three clusters, respectively (P=2.9×10−5). As polyphen
employs sequence, phylogenetic and structural information for
characterizing substitutions the differential effect of the clusters on
Fig. 2. Sequence-based properties of substitutions among the three clusters. (A) Evolutionary tolerance of the substitution as evaluated by PSIC. Preponderance of cluster 3
substitutions (74%) can be seen at PSIC values greater than 2.0 while most of the substitutions in the other two clusters (81.8% and 66.7% in clusters 1 and 2, respectively) have PSIC
values less than 2.0. (B) Importance of evolutionary conservation on mutational effect as determined by SIFT analysis. Very few mutations in cluster 3 (10%) were classiﬁed as
tolerated (tolerance score≥0.05) compared to clusters 1 and 2 (54.5% and 39.4%, respectively). (C) Fraction of radical and conservative substitutions obtained based on the Grantham
Difference (GD). Nearly half (46.5%) of cluster 3 substitutions were radical while preponderant substitutions in clusters 1 and 2 (81.8% and 88% respectively) were conservative.
Fig. 3. Hemophilia B as a quasi-quantitative condition: A paradigm shift. The schema presents the spectrum of human genetic diseases and the repositioning of hemophilia B from a
simple monogenic disease to that showing variable expressivity. It is noteworthy that while a majority of mutations show phenotypic homogeneity, certain mutations exhibit
variable expressivity which could be because of oligogenic or environmental effects or both. With allelic heterogeneity in F9 and phenotypic heterogeneity in its clotting activity,
hemophilia B can be considered as quasi-quantitative condition that provides a link between simple monogenic and complex polygenic human diseases.
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Table 1
Mutations shown to cause only mild hemophilia B (6–30% clotting activity) in repeated
reports in Haemophilia B mutation database.
S. No. Mutation/effect
(traditional
nomenclature)a
Mutation/effect
(approved
nomenclature)b
No. of
reportsc
Geometric
meand
Mean deviation
about the
geometric meand
(1) 6385GNA c.148GNA 5 17.67 3.47
Gly4Ser p.Gly50Ser
(2) 6461GNA c.224GNA 14 27.58 7.86
Arg29Gln p.Arg75Gln
(3) 6488CNT c.251CNT 4 9.70 2.78
Thr38Ile p.Thr84Ile
(4) 10394GNA c.280GNA 3 26.95 1.35
Gly48Arg p.Gly94Arg
(5) 10415CNG c.301CNG 7 8.09 2.16
Pro55Ala p.Pro101Ala
(6) 30924ANG c.941ANG 4 7.26 1.63
His268Arg p.His314Arg
(7) 30998ANG c.1015ANG 3 21.32 5.11
Lys293Glu p.Lys339Glu
(8) 31007ANG c.1024ANG 3 22.10 4.70
Thr296Ala p.Thr342Ala
(9) 31016TNG c.1033TNG 3 10.97 2.34
Phe299Val p.Phe345Val
(10) 31041TNC c.1058CNT 7 16.43 1.50
Val307Ala p.Val353Ala
(11) 31122CNA c.1139CNA 3 15.59 9.00
Ala334Asp p.Ala380Asp
(12) 31328CNT c.1345CNT 10 27.88 5.93
Arg403Trp p.Arg449Trp
(13) 31329GNA c.1346GNA 7 27.53 7.06
Arg403Gln p.Arg449Gln
a Nucleotide numbering for traditional nomenclature of mutations has been done in
accordance with Yoshitake et al. [24] and that of amino acid with respect to the
processed mature protein.
b cDNA numbering is based on reference sequence GenBank NM_000133.2; 1
corresponds to the A of the ATG initiation translation codon; Amino acid numbering is
done with respect to the primary translation product; the translation initiator Met is
numbered as +1. Mutation nomenclature is as prescribed [25,26].
c All reports from Haemophilia B mutation database.
d Reports that had no ambiguity about the independence of the reported mutations
alone were considered. Reports of female carriers and double mutants were excluded.
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accessibility of the mutant sites or the types of changes affected,
effect of the substitutions on protein stability determined by
I-Mutant 2.0 did not show any signiﬁcant differences among the
three clusters. Secondary structure predictions of the mutant sites
yielded similar results with most of the mutations concentrating in
the coils. Hence, we checked for differential distribution of these
substitutions in the disordered regions of the protein. PONDR-VLXT
predicted the existence of very few mutations (27%, 18% and 20% in
cluster 1, 2 and 3, respectively) in the disordered regions. Thus we
could not ﬁnd any differences in the structural attributes.
Therefore, mutations showing phenotypic homogeneity were
characterized by increased evolutionary conservation of mutant
sites and evolutionarily least tolerated radical substitutions. In
contrast, mutations showing phenotypic variation were characterized
by relatively less conserved mutant sites and more tolerated
conservative substitutions. This variationmight result from oligogenic
effects with a single major locus (F9) as observed in certain other
diseases [7]. While some F9 mutations show perfect colinearity with
phenotype, others do not, probably owing to their tendency to be
affected by modiﬁers accounting for variable expressivity (Fig. 3).
However, very little is known about the modiﬁers affecting factor IX
levels. The only available evidence in this regard suggests that the
heritable component of the inter-individual factor IX variability
involves a collection of Quantitative Trait Loci with modest effects
that may reside in genes other than F9 [4,8,]. The differences in the
sequence properties may thus be a part of the spectrum that
inﬂuences phenotypic variance. Furthermore, we demonstrate here
that consideration of continuous phenotypes renders quantitative
rigor for interrogation and hence higher predictive value while
analyzing for differential properties than classiﬁcations based on
clinical end points as was previously attempted [4].
We also identiﬁed that certain mutations have been consistently
reported to cause mild hemophilia B (Table 1). Some of these
mutations show phenotypic plasticity as represented by mean
deviation about the geometric mean in Table 1 and cluster-based
classiﬁcation in Supplementary Table 1. Notwithstanding this pheno-
typic plasticity, they consistently cause only milder form of the
disease, as reﬂected by the geometric mean (Table 1). Prenatal
diagnosis is often remarked as a “seek and destroy mission” with
pregnancy termination being the dominant management strategy.
We believe that the improving health care management system can
ensure a normal life for the less than perfect babies carrying such
mutations consistently leading tomild hemophilia B [9,10]. Thismight
serve as a ﬁrst step in phenotyping through genotyping and
quantifying fetal abnormality, with applications in genetic counseling.
However, absence of clinical information including factor IX transfu-
sions, age at the ﬁrst symptom, etc. in the Haemophilia B mutation
database warrants careful interpretation of these observations.
Acquiring complete clinical information for such mutations would
have strong implications on indiscriminate pregnancy terminations.
We reckon that such an analysis in other genetic diseases would prove
beneﬁcial in managing human congenital genetic diseases.
Methods
Dataset and classiﬁcation of mutations
We retrieved 201 missense mutations that have been reported at
least twice with clotting activity in Haemophilia B mutation database
[5]. Clotting activities of each such mutation was used to derive mean
deviation about the geometric mean as follows.
ga = exp
1
n
Xn
i=1
ln ci
 !
ð1Þwhere ga is the geometric mean of clotting activities (Ci) reported for
each characterization of mutation a
Ma =
1
n
Xn
i=1
abs ci − gað Þ
 !
ð2Þ
where Ma is the mean deviation about the geometric mean for
mutation a; abs is the absolute value of the difference.
We classiﬁed the mutations by unsupervised learning using K-
means clustering into three clusters. The method uses k random
points as initial centroids of the k clusters and then assigns each data
point to that cluster for which the Euclidean distance between the
data point and the centroid is minimum. After all the data points have
been assigned, the centroids are recalculated as the means of the data
points of the different clusters. The process is repeated till the
assignments remain unchanged in two successive steps. The optimal
choice of k, the number of clusters, can be determined by minimizing
the Akaike Information Criterion (AIC) based on the ratio of the
variation between the clusters to the variation within the clusters.
Evaluation of sequence and structure-based properties
Evolutionary conservation of mutant sites was deﬁned by tradi-
tional qualitative descriptors [11] and quantitative descriptor-
scorecons [12]. Based on the traditional method of evaluating
evolutionary conservation of mutant sites [11], a residue was termed
“generic” if it is identical in all species of factor IX and in the three
437S. Chavali et al. / Genomics 94 (2009) 433–437related blood coagulation serine proteases: factor VII (encoded by
F7), factor X (encoded by F10) and protein C (encoded by PROC).
A residue identical in all species of a factor IX and identical in one or
two of the related proteases was termed “partially generic.” A “factor
IX speciﬁc” residue was identical in all species of factor IX but not in
the three related proteases. If non-conservatively substituted in any
species of factor IX, the residue is classiﬁed as “non-conserved.”
Evolutionary tolerance of the substitution was assessed by calculat-
ing Position Speciﬁc Independent Counts difference (PSIC) using
Polyphen server [13,14]. The impact of evolutionary conservation on
substitution was also assessed by using Sorting Intolerant From
Tolerant (SIFT) server [15]. Based on a tolerance score SIFT classiﬁes
substitutions into tolerant (score≥ 0.05) and deleterious
(scoreb0.05). Physicochemical constraint violation mediated by
these missense changes was evaluated by calculating Multivariate
Analysis of Protein Polymorphism (MAPP) score [16]. Based on the
Grantham score difference [17] (GD, calculated using AlignGVGD)
we identiﬁed the substitutions as either radical (GDN100) or
conservative (GDb100). Polyphen was used to assess the impact of
the variations on structure and hence function by classifying
variations as benign, possibly damaging and probably damaging
[14]. RVP-net which provides real predictions of accessible surface
area was employed to predict solvent accessibility of mutant sites
and the mutants as either buried or exposed [18]. Effect of these
mutations on protein stability as either increase or decrease was
assessed by I-Mutant 2.0 at pH 7.0 and temperature 25 °C [19].
Secondary structure elements were identiﬁed as helix, strand or coil
using PSIPRED [20]. Prediction of intrinsic disorder segments was
done using PONDR VL-XT [21]. Brieﬂy, disorder segments are those
that fail to self-fold into a ﬁxed 3D structure which might exist
in native state [22]. The detailed methodological procedures for
studying each of these properties have been provided in our previous
report [4].
Statistical analysis for comparisons
Continuous variables like scorecons, MAPP and PSIC were assessed
for differences using One-way ANOVA test followed by Dunnett's pair-
wise tests (SPSS package). A P value less than 0.017 for these pairwise
comparisons was considered signiﬁcant (Bonferroni correction;
α=0.05/3=0.017). Different classes of parameters, as appropriate,
were compared using χ2 test for trend and Fisher's exact test as
appropriate and 2×N contingency tables were checked by means of
10,000 simulations using CLUMP version 2.2 [23].
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